Global Menopausal Disorder Treatment Market, By Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Creams, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the menopausal disorder treatment market is anticipated to grow rapidly during the forecast period. Menopause is one of the most physically demanding times in a women’s life, prompting worldwide pharmaceutical companies to create effective medications to treat it and related problems. Menopause, also known as the climatic period, occurs when a woman’s menstrual periods stop occurring permanently. Numerous significant changes occur in the female body during this time, resulting in the emergence of several illnesses. Menopausal problems are becoming more common in all parts of the world, and healthcare organizations support the development and use of medications that can effectively treat them. It also has prompted pharmaceutical firms to develop and market medications that alleviate the long term symptoms of menopausal illnesses in women and do not affect their health during or after treatment.
Data Bridge Market Research analyses that the menopausal disorder treatment market was valued at USD 11,860.10 million in 2021 and is expected to reach USD 21,790.13 million by 2029, registering a CAGR of 7.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Menopausal Syndrome refers to the symptoms that accompany the physiological changes that occur in a woman's body when her reproductive years come to an end. Menopause is a natural female hormone deficiency that happens between the ages of 45 and 55. It is a typical result of the ageing process. The ovaries gradually become less active and produce less sex hormone throughout this time (estrogen and progesterone). As a result, menstruation is no longer possible. If a woman has not had a monthly cycle for a year and has no underlying cause, she is usually considered menopausal.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Creams, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), Eli Lilly and Company (US), Abbott (US), Novo Nordisk A/S (Denmark), Allergan (Ireland), Dr. Reddy’s Laboratories Ltd. (India), TherapeuticsMD, Inc. (US), Ipsen Pharma (France), Besins Healthcare (Belgium), Mithra Pharmaceuticals (Belgium), Aché Laboratórios Farmacêuticos S.A (Brazil), SEBELA PHARMACEUTICALS (US), Fervent Pharmaceuticals Inc. (US), KaNDy Therapeutics (UK), Duchesnay USA (US)
|
Market Opportunities
|
|
Menopausal Disorder Treatment Market Dynamics
Drivers
- Rise in the prevalence of menopausal disorder
The rising prevalence of menopausal disorder is estimated to propel the menopausal disorder treatment market's growth. Along with this, increasing cases of hormonal therapy, radiation therapy and hysterectomy will influence the market’s growth rate.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of menopausal disorder treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness and technological advancement will expand the menopausal disorder treatment market. Additionally, high disposable income and continuously changing lifestyle will expand the menopausal disorder treatment market. Along with this, rising geriatric population and surging cases of hormone-related disorders will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the menopausal disorder treatment market growth. Along with this, rising drug approvals and launch of innovative products will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the menopausal disorder treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the hormonal therapy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the menopausal disorder treatment market. Additionally, lack of awareness and side effects of medication will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This menopausal disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the menopausal disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Menopausal disorder treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Menopausal Disorder Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the antifungal drugs market.
Global Menopausal Disorder Treatment Market Scope
The menopausal disorder treatment market is segmented on the basis of stages, type, menopause symptoms, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Stages
- Menopause
- Postmenopause
- Perimenopause
On the basis of stages, the menopausal disorder treatment market is segmented into perimenopause, menopause and postmenopause.
Type
- Hormonal Therapy
- Non-Hormonal Therapy
On the basis of type, the menopausal disorder treatment market is segmented into hormonal therapy and non-hormonal therapy.
Menopause Symptoms
- Vasomotor Symptoms
- Atrophic Vaginitis
- Osteoporosis
- Joint Pain
- Weight Gain
- Dyspareunia
- Depression
- Others
On the basis of menopause symptoms, the menopausal disorder treatment market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, depression, joint pain, weight gain and others.
Dosage Form
- Tablet
- Creams
- Gels
- Rings/Insert
- Patch/Film
- Injection Shot
- Spray
- Others
On the basis of dosage form, the menopausal disorder treatment market is segmented into tablet, cream, gels, patch/film, rings, spray, injection shot and others.
Route of Administration
- Oral
- Vaginal
- Transdermal
- Parenteral
On the basis of route of administration, the menopausal disorder treatment market is segmented into oral, parenteral, transdermal and vaginal.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the menopausal disorder treatment market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the menopausal disorder treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Menopausal Disorder Treatment Market Regional Analysis/Insights
The Menopausal disorder treatment market is analysed and market size insights and trends are provided by country, stages, type, menopause symptoms, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Menopausal disorder treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the menopausal disorder treatment market because of the presence of major key players and well-established healthcare infrastructure in this region. Additionally, the increase in the number of elder female population will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to the growing prevalence of menopausal disorder in this region. Also, the development of healthcare infrastructure and rising number of research activities will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Menopausal Disorder Treatment Market Share Analysis
The Menopausal disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to menopausal disorder treatment market.
Some of the major players operating in the menopausal disorder treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- Eli Lilly and Company (US)
- Abbott (US)
- Novo Nordisk A/S (Denmark)
- Allergan (Ireland)
- Dr. Reddy’s Laboratories Ltd. (India)
- TherapeuticsMD, Inc. (US)
- Ipsen Pharma (France)
- Besins Healthcare (Belgium)
- Mithra Pharmaceuticals (Belgium)
- Aché Laboratórios Farmacêuticos S.A (Brazil)
- SEBELA PHARMACEUTICALS (US)
- Fervent Pharmaceuticals Inc. (US)
- KaNDy Therapeutics (UK)
- Duchesnay USA (US)
SKU-